Skip to main content

What type of prostate cancer is Erleada used to treat?

Medically reviewed by drugclasses.com. Last updated on Sep 11, 2023.

Official answer

by drugclasses.com

Erleada (apalutamide) is used for the treatment of metastatic castration-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer.

Metastatic castration-sensitive prostate cancer (mCSPC) refers to prostate cancer that still responds to androgen deprivation therapy (ADT) and has spread to other parts of the body.

Non-metastatic castration-resistant prostate cancer (NM-CRPC) refers to prostate cancer that no longer responds to androgen deprivation therapy (ADT) or surgical treatments that lower testosterone, but has not yet been discovered in other parts of the body.

Erleada is an androgen receptor inhibitor. It works by blocking the effect of androgens on the tumor. Androgens, such as testosterone, can promote tumor growth.

Erleada is taken orally, once daily, with or without food.

Read next

What is the mechanism of action for Erleada?

Erleada is an oral medicine for prostate cancer that works by blocking the effects of androgen. Androgens are male hormones (like testosterone) that are needed for prostate function but can also stimulate cancer growth. Blocking androgens can help stop the growth and spread of prostate cancer cells. Continue reading

What is the strongest chemotherapy drug for breast cancer?

Doxorubicin is considered one of the strongest chemotherapy drugs for breast cancer ever invented. It can kill cancer cells at every point in their life cycle, and it's used to treat a wide variety of cancers, not just breast cancer. Doxorubicin is also known as “The Red Devil” because it is a clear bright red color. It can cause your urine or other body fluids to turn a reddish color for 1 to 2 days after a dose is given, which is normal and temporary. Continue reading

Is small cell or non-small cell lung cancer worse?

Generally, small cell lung cancer (SCLC) is worse than non-small cell lung cancer (NSCLC). SCLC accounts for about 10-15% of people who have lung cancer and is the most aggressive form of lung cancer. SCLC usually starts in the breathing tubes (bronchi), and although the cells are small, they grow very quickly and create large tumors. Early on in the course of the disease, there are rarely any symptoms. If caught early (limited-stage disease) 20-25% of people can be potentially cured. Extensive SCLC is more difficult to treat. Continue reading

Related medical questions

Drug information

Related support groups